| First Author | Dong G | Year | 2023 |
| Journal | Cell Metab | Volume | 35 |
| Issue | 2 | Pages | 332-344.e7 |
| PubMed ID | 36634673 | Mgi Jnum | J:333101 |
| Mgi Id | MGI:7434052 | Doi | 10.1016/j.cmet.2022.12.012 |
| Citation | Dong G, et al. (2023) Palmitoylation couples insulin hypersecretion with beta cell failure in diabetes. Cell Metab 35(2):332-344.e7 |
| abstractText | Hyperinsulinemia often precedes type 2 diabetes. Palmitoylation, implicated in exocytosis, is reversed by acyl-protein thioesterase 1 (APT1). APT1 biology was altered in pancreatic islets from humans with type 2 diabetes, and APT1 knockdown in nondiabetic islets caused insulin hypersecretion. APT1 knockout mice had islet autonomous increased glucose-stimulated insulin secretion that was associated with prolonged insulin granule fusion. Using palmitoylation proteomics, we identified Scamp1 as an APT1 substrate that localized to insulin secretory granules. Scamp1 knockdown caused insulin hypersecretion. Expression of a mutated Scamp1 incapable of being palmitoylated in APT1-deficient cells rescued insulin hypersecretion and nutrient-induced apoptosis. High-fat-fed islet-specific APT1-knockout mice and global APT1-deficient db/db mice showed increased beta cell failure. These findings suggest that APT1 is regulated in human islets and that APT1 deficiency causes insulin hypersecretion leading to beta cell failure, modeling the evolution of some forms of human type 2 diabetes. |
